《嘉德诺Cardinal Health(CAH)2023财年第二季度财报(英文版)(15页).pdf》由会员分享,可在线阅读,更多相关《嘉德诺Cardinal Health(CAH)2023财年第二季度财报(英文版)(15页).pdf(15页珍藏版)》请在三个皮匠报告上搜索。
1、Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance Revenue increased 13%to$51.5 billion GAAP1 operating loss was$119 million due to a non-cash,pre-tax goodwill impairment of$709 million related to the M
2、edical segment;GAAP diluted loss per share was$0.50 Non-GAAP operating earnings of$467 million were in-line with the second quarter of last year;non-GAAP diluted EPS increased 4%to$1.32 Fiscal year 2023 non-GAAP EPS guidance raised to$5.20 to$5.50,from$5.05 to$5.40 DUBLIN,Ohio,February 2,2023 Cardin
3、al Health(NYSE:CAH)today reported second quarter fiscal year 2023 revenues of$51.5 billion,an increase of 13%from the second quarter of fiscal year 2022.Second quarter GAAP operating loss was$119 million due to a non-cash,pre-tax goodwill impairment of$709 million related to the Medical segment.GAAP
4、 diluted loss per share was$0.50,primarily due to this impairment,net of tax effects.Second quarter non-GAAP operating earnings of$467 million were in-line with the second quarter of last year.Non-GAAP diluted earnings per share(EPS)increased 4%to$1.32,due to lower interest expense and a lower share
5、 count,partially offset by a higher non-GAAP effective tax rate.Our second quarter results demonstrate continued momentum against our plans,led by better-than-expected performance in the Pharmaceutical segment and Medical results in-line with our prior commentary,”said Jason Hollar,CEO of Cardinal H
6、ealth.With the first half of fiscal year 2023 behind us,we are pleased to raise our full year non-GAAP EPS guidance and outlook for the Pharmaceutical segment.In the Medical segment,we remain confident in our Medical Improvement Plan,including the actions we are taking to mitigate supply chain infla